Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 32, Issue 6, Pages 1025-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2018.07.011
Keywords
Immunotherapy; Adoptive T-cell therapy; Neoantigens; Cancer vaccines; Checkpoint blockade; Oncolytic virotherapy; Cancer testis antigens; IDO inhibition
Categories
Funding
- Roswell Park Alliance Foundation, RPCI-UPCI Ovarian Cancer SPORE [P50CA159981-01A1]
- National Cancer Institute [P30CA016056]
- NATIONAL CANCER INSTITUTE [P30CA016056, P50CA159981] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Clinical progress in cancer immunotherapy has been slow; however, within the last 5 years, breakthrough successes have brought immunotherapy to the forefront in cancer therapy. Promising results have been observed in solid tumors and hematologic malignancies. Most treatment modalities have shown limited efficacy as monotherapy. The complex nature of cancer and the immunosuppressive microenvironment emphasizes the need to personalize immunotherapy by manipulating the patient's own immune system. For successful and long-lasting cure of cancer, a multimodal approach is essential, combining antitumor cell therapy with manipulation of multiple pathways in the tumor microenvironment to ameliorate tumor-induced immunosuppression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available